(Q54055764)
Statements
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). (English)
R Morant
J Bernhard
R Maibach
M Borner
M F Fey
B Thürlimann
E Jacky
F Trinkler
J Bauer
G Zulian
S Hanselmann
C Hürny
F Hering
1 February 2000
11
2
183-188